Earnings Releases·Nov 4, 2026, 4:25 PM ET

Innoviva — Third Quarter 2026 Earnings Summary

Total revenue decreased 1.6% year-over-year to $106.1 million, driven by a decline in royalty revenue, while U.S. net product sales surged 45% to $43.3 million; income from operations rose 21.9% to $42.2 million, though a net loss of $73.9 million resulted from a $139.5 million unfavorable change in the fair value of investments.
The company reaffirmed its 2026 guidance to achieve at least $150 million in U.S. net product sales, citing strong commercial momentum for GIAPREZA®, XACDURO®, and the newly launched NUZOLVENCE®, alongside updated IDSA guidance positioning XACDURO® as a preferred treatment for CRAB infections.
Management executed a share repurchase program, buying back 1,226,948 shares for $26.3 million in Q3 (totaling $82.7 million since inception), while maintaining a robust balance sheet with $581.4 million in cash and $535.5 million in strategic healthcare investments.